Drugs / TY-2699a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05866692 | Aug 2023 → Oct 2025 overdue | cancer | TYK Medicines, Inc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TY-2699a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05866692 ↗ |
| Route | Oral | “Administered Orally” NCT05866692 ↗ |